These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 22234089)

  • 1. Core biopsies of the breast: diagnostic pitfalls.
    Joshi M; Reddy SJ; Nanavidekar M; Russo JP; Russo AV; Pathak R
    Indian J Pathol Microbiol; 2011; 54(4):671-82. PubMed ID: 22234089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic accuracy and prognostic value of core biopsy in the management of breast cancer: a series of 542 patients.
    Richter-Ehrenstein C; Müller S; Noske A; Schneider A
    Int J Surg Pathol; 2009 Aug; 17(4):323-6. PubMed ID: 19029173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.
    Parise CA; Bauer KR; Brown MM; Caggiano V
    Breast J; 2009; 15(6):593-602. PubMed ID: 19764994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of core needle biopsy (CNB) and surgical specimens for accurate preoperative evaluation of ER, PgR and HER2 status of breast cancer patients.
    Tamaki K; Sasano H; Ishida T; Miyashita M; Takeda M; Amari M; Tamaki N; Ohuchi N
    Cancer Sci; 2010 Sep; 101(9):2074-9. PubMed ID: 20557310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of immunohistochemical staining for oestrogen receptor, progesterone receptor and HER-2 in breast core biopsies and subsequent excisions.
    Wood B; Junckerstorff R; Sterrett G; Frost F; Harvey J; Robbins P
    Pathology; 2007 Aug; 39(4):391-5. PubMed ID: 17676479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reliance on hormone receptor assays of surgical specimens may compromise outcome in patients with breast cancer.
    Mann GB; Fahey VD; Feleppa F; Buchanan MR
    J Clin Oncol; 2005 Aug; 23(22):5148-54. PubMed ID: 16051956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical detection of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression in breast carcinomas: comparison on cell block, needle-core, and tissue block preparations.
    Hanley KZ; Birdsong GG; Cohen C; Siddiqui MT
    Cancer; 2009 Aug; 117(4):279-88. PubMed ID: 19551847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The accuracy of preoperative core biopsy in determining histologic grade, hormone receptors, and human epidermal growth factor receptor 2 status in invasive breast cancer.
    Park SY; Kim KS; Lee TG; Park SS; Kim SM; Han W; Noh DY; Kim SW
    Am J Surg; 2009 Feb; 197(2):266-9. PubMed ID: 18614146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The association of infrared imaging findings of the breast with hormone receptor and human epidermal growth factor receptor 2 status of breast cancer.
    Wang J; Shih TT; Yen RF; Lu YS; Chen CY; Mao TL; Lin CH; Kuo WH; Tsai YS; Chang KJ; Chien KL
    Acad Radiol; 2011 Feb; 18(2):212-9. PubMed ID: 21126889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 17 beta-Hydroxysteroid dehydrogenase type 1 and type 2 in ductal carcinoma in situ and intraductal proliferative lesions of the human breast.
    Ariga N; Moriya T; Suzuki T; Kimura M; Ohuchi N; Satomi S; Sasano H
    Anticancer Res; 2000; 20(2B):1101-8. PubMed ID: 10810403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunochemistry for oestrogen receptor, progesterone receptor and HER2 on cell blocks in primary breast carcinoma.
    Kumar SK; Gupta N; Rajwanshi A; Joshi K; Singh G
    Cytopathology; 2012 Jun; 23(3):181-6. PubMed ID: 21375607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of steroid receptors and HER 2/neu in breast cancer biopsies of women living in Puerto Rico.
    Colón E; Reyes JS; González Keelan C; Climent-Peris C
    P R Health Sci J; 2002 Dec; 21(4):299-303. PubMed ID: 12572236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Obesity and risk of the less commonly diagnosed subtypes of breast cancer.
    Stark A; Schultz D; Kapke A; Nadkarni P; Burke M; Linden M; Raju U
    Eur J Surg Oncol; 2009 Sep; 35(9):928-35. PubMed ID: 19121564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Flat epithelial atypia is a common subtype of B3 breast lesions and is associated with noninvasive cancer but not with invasive cancer in final excision histology.
    Noske A; Pahl S; Fallenberg E; Richter-Ehrenstein C; Buckendahl AC; Weichert W; Schneider A; Dietel M; Denkert C
    Hum Pathol; 2010 Apr; 41(4):522-7. PubMed ID: 20004938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Basal breast cancer molecular subtype predicts for lower incidence of axillary lymph node metastases in primary breast cancer.
    Crabb SJ; Cheang MC; Leung S; Immonen T; Nielsen TO; Huntsman DD; Bajdik CD; Chia SK
    Clin Breast Cancer; 2008 Jun; 8(3):249-56. PubMed ID: 18650155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Do the histologic features and results of breast cancer biomarker studies differ between core biopsy and surgical excision specimens?
    Burge CN; Chang HR; Apple SK
    Breast; 2006 Apr; 15(2):167-72. PubMed ID: 16095904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biopathologic profile of breast cancer core biopsy: is it always a valid method?
    Cavaliere A; Sidoni A; Scheibel M; Bellezza G; Brachelente G; Vitali R; Bucciarelli E
    Cancer Lett; 2005 Jan; 218(1):117-21. PubMed ID: 15639347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tissue microarray-based immunohistochemical study can significantly underestimate the expression of HER2 and progesterone receptor in ductal carcinoma in situ of the breast.
    Lin Y; Hatem J; Wang J; Quinn A; Hicks D; Tang P
    Biotech Histochem; 2011 Oct; 86(5):345-50. PubMed ID: 20701550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surgical specimen can be replaced by core samples in assessment of ER, PR and HER-2 for invasive breast cancer.
    Sutela A; Vanninen R; Sudah M; Berg M; Kiviniemi V; Rummukainen J; Kataja V; Kärjä V
    Acta Oncol; 2008; 47(1):38-46. PubMed ID: 17851859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.